Literature DB >> 11706215

Complications of endoscopic retrograde cholangiopancreatography: spectrum of abnormalities demonstrated with CT.

H K Pannu1, E K Fishman.   

Abstract

Endoscopic retrograde cholangiopancreatography (ERCP) is an invasive procedure that is performed to diagnose and treat pancreatic and biliary disease. In approximately 5%-10% of cases, the procedure itself causes adverse events. Diagnosis and management of ERCP-induced complications are performed with clinical, laboratory, and radiologic procedures. Evaluation of the type and severity of the complication is necessary and is successfully performed with computed tomography (CT). The most common causes of post-ERCP pain are acute pancreatitis and duodenal perforation. In severe pancreatitis, the pancreas is enlarged and enhances heterogeneously at CT. Pancreatic enhancement is diminished in areas of glandular necrosis. In duodenal perforation, CT may reveal extraluminal air or fluid. CT findings of acute duodenal hemorrhage are duodenal wall thickening and a high-attenuation mass in the duodenal wall. In infection, the bile ducts can be dilated and the attenuation of the bile can be increased at CT. Abscesses appear as hypoattenuating masses with enhancing capsules. CT findings of stent migration are an atypical location of the stent and bowel impaction. Other complications of ERCP are those related to endoscopy and include esophageal, liver, and splenic injury.

Entities:  

Mesh:

Year:  2001        PMID: 11706215     DOI: 10.1148/radiographics.21.6.g01nv101441

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  23 in total

1.  Retroduodenal perforation without sphincterotomy: a case report.

Authors:  John Menachery; Yogesh Chawla; Ajay Duseja; Radha K Dhiman; Naveen Kalra; Sameer Vankar
Journal:  Dig Dis Sci       Date:  2010-12-08       Impact factor: 3.199

2.  An Unexpected Complication of Endoscopic Retrograde Cholangiopancreatography with a Novel Treatment Approach.

Authors:  Jeremy Polman; Aaron C Williams; Gaetano Ruggiero; Aaron DeWitt
Journal:  Case Rep Gastroenterol       Date:  2020-11-04

3.  Case series: pneumoretroperitoneum secondary to duodenal perforation after endoscopic retrograde cholangiopancreatography.

Authors:  Jaime Ruiz-Tovar; Eduardo Lobo; Alfonso Sanjuanbenito; Enrique Martínez-Molina
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

Review 4.  [Retroperitoneal emphysema after endoscopic retrograde cholangiopancreatography].

Authors:  T Vowinkel; N Senninger
Journal:  Chirurg       Date:  2015-05       Impact factor: 0.955

Review 5.  Complications of minimally invasive procedures of the abdomen and pelvis: a comprehensive update on the clinical and imaging features.

Authors:  Prashanth Saddala; Subramaniyan Ramanathan; Sree Harsha Tirumani; Vijayanadh Ojili; Arpit M Nagar; Najla Fasih; Adnan Sheikh; Sachin S Saboo
Journal:  Emerg Radiol       Date:  2014-12-24

Review 6.  Predicting and preventing post-ERCP pancreatitis.

Authors:  John Baillie
Journal:  Curr Gastroenterol Rep       Date:  2002-04

7.  Use of diffusion-weighted imaging in the noninvasive diagnostic of obstructed biliary ducts.

Authors:  Eliane Donato Leite Paro; Andrea Puchnick; Jacob Szejnfeld; Suzan Menasce Goldman
Journal:  Abdom Radiol (NY)       Date:  2020-07-14

Review 8.  Blunt pancreatic trauma: A persistent diagnostic conundrum?

Authors:  Atin Kumar; Ananya Panda; Shivanand Gamanagatti
Journal:  World J Radiol       Date:  2016-02-28

Review 9.  Upper gastrointestinal endoscopy: expected post-procedural findings and adverse events.

Authors:  Tarek N Hanna; Saurabh Rohatgi; Haris N Shekhani; Fatima Shahid; Vijayanadh Ojili; Faisal Khosa
Journal:  Emerg Radiol       Date:  2016-07-26

10.  Operative and non-operative management of endoscopic retrograde cholangiopancreatography-associated duodenal injuries.

Authors:  M Ezzedien Rabie; N H Mir; M S Al Skaini; I El Hakeem; A Hadad; H Ageely; A N Shaban; M Obaid; A M Hummadi
Journal:  Ann R Coll Surg Engl       Date:  2013-05       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.